



Avid Bioservices Appoints Michael Alston, Jr. as Vice President, Operations

September 22, 2022

Accomplished Operations Professional Promoted from Role as Director of Project Engineering; Credited with Leading All of the Company's Ongoing Facility Expansion Projects

TUSTIN, Calif., Sept. 22, 2022 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient lives by providing high quality development and manufacturing services to biotechnology and pharmaceutical companies, today announced the appointment of Michael Alston, Jr. as vice president, operations. Mr. Alston was promoted from Avid's director of project engineering, a role in which he led all of the company's ongoing facility expansions. In his new position, he will continue to oversee these projects including the Myford South expansion, as well as the construction of Avid's new dedicated cell and gene therapy facility.

Mr. Alston has more than 15 years of experience spanning operational and capital management responsibilities supporting cGMP manufacturing, facilities, engineering, and environmental, health and safety (EHS) functions. Prior to joining Avid in 2019, Mr. Alston was associate director, engineering and facilities with Sterogene Bioseparations, where he led the biotechnology company's engineering, facilities, maintenance, safety and environmental functions. During this time, he led the design, construction and launch of Sterogene's new, more than \$5 million cGMP laboratory and pilot plant manufacturing facility. Mr. Alston has also previously served in senior roles within Merck's viral vaccine manufacturing unit, including senior manufacturing supervisor. His career has included senior engineering, facilities and operational management positions with Unilever and ConAgra Foods.

"Michael's promotion to vice president, operations, is well deserved based on the exceptional job he has done leading and overseeing our multiple facility expansion and buildout projects, which are complex and occurring concurrently. His extensive background in both engineering and operations is ideally suited for his new role and the responsibilities that come with the position. We are thrilled to be able to promote such a talented individual from within Avid to this key role and look forward to Michael's continued contributions to the company's success," said Nick Green, president and chief executive officer of Avid Bioservices.

About Avid Bioservices, Inc.

Avid Bioservices (NASDAQ:CDMO), an S&P SmallCap 600 company, is a dedicated contract development and manufacturing organization (CDMO) focused on development and cGMP manufacturing of biologics. The company provides a comprehensive range of process development, cGMP clinical and commercial manufacturing services for the biotechnology and biopharmaceutical industries. With 29 years of experience producing monoclonal antibodies and recombinant proteins, Avid's services include cGMP clinical and commercial drug substance manufacturing, bulk packaging, release and stability testing and regulatory submissions support. For early-stage programs the company provides a variety of process development activities, including upstream and downstream development and optimization, analytical methods development, testing and characterization. The scope of our services ranges from standalone process development projects to full development and manufacturing programs through commercialization. www.avidbio.com

Contacts:

Stephanie Diaz (Investors)
Vida Strategic Partners
415-675-7401
sdiaz@vidasp.com

Tim Brons (Media)
Vida Strategic Partners
415-675-7402
tbrons@vidasp.com



Source: Avid Bioservices, Inc